immatics biotechnologies GmbH (NASDAQ:IMTXW) Short Interest Up 21.2% in October

immatics biotechnologies GmbH (NASDAQ:IMTXW) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 4,000 shares, an increase of 21.2% from the October 15th total of 3,300 shares. Based on an average trading volume of 11,600 shares, the short-interest ratio is presently 0.3 days.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Aristeia Capital LLC lifted its stake in immatics biotechnologies by 3,293.6% in the fourth quarter. Aristeia Capital LLC now owns 754,590 shares of the company’s stock worth $1,856,000 after purchasing an additional 732,354 shares during the last quarter. Privium Fund Management B.V. bought a new stake in immatics biotechnologies in the second quarter worth about $1,461,000. Alyeska Investment Group L.P. bought a new stake in immatics biotechnologies in the fourth quarter worth about $529,000. Walleye Capital LLC lifted its stake in immatics biotechnologies by 25.7% in the second quarter. Walleye Capital LLC now owns 260,079 shares of the company’s stock worth $889,000 after purchasing an additional 53,153 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in immatics biotechnologies by 11.9% in the second quarter. JPMorgan Chase & Co. now owns 378,197 shares of the company’s stock worth $1,293,000 after purchasing an additional 40,168 shares during the last quarter.

immatics biotechnologies Stock Down 16.7 %

Shares of NASDAQ:IMTXW opened at $2.50 on Thursday. immatics biotechnologies has a 12 month low of $1.20 and a 12 month high of $4.14. The company has a 50-day moving average price of $2.86 and a 200 day moving average price of $3.09.

immatics biotechnologies Company Profile

immatics is a clinical-stage biopharmaceutical company active in the discovery and development of t-cell redirecting immunotherapies for the treatment of cancer. our transformative product candidates are – best in class – adoptive cell therapies and bispecific tcr molecules. these products are directed against tumor targets that have been identified and validated by immatics’​ proprietary and world-leading xpresident® technology.